[24 January 2014]
Products Affected - Description
Naltrexone 50 mg Oral Tablets, Sandoz
100 count (NDC 00185-0039-01) - discontinued
Reason for the Shortage
- Teva discontinued Revia 50 mg tablets in 100 count packages in early 2012.
- Teva had naltrexone on shortage due to raw material issues.
- Sandoz discontinued naltrexone 50 mg tablets.
Naltrexone 50 mg Oral Tablets, Covidien
100 count (NDC 00406-1170-01)
30 count (NDC 00406-1170-03)
Naltrexone 50 mg Oral Tablets, Teva
100 count (NDC 00555-0902-02)
30 count (NDC 00555-0902-01)
Revia 50 mg Oral Tablets, Teva
30 count (NDC 51285-0275-01)
Estimated Resupply Dates
All presentations are currently available.
January 24, 2014; November 11, 2013; September 19, 2013; July 18, 2013; May 10, 2013; March 22, 2013; February 1, 2013; December 14, 2012; November 16, 2012; September 5, 2012; July 13, 2012; June 18, 2012; April 20, 2012; February 21, 2012; January 19, 2012; January 3, 2012; December 19, 2011, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins